Lung disease in alpha-1-antitrypsin deficiency (AATD) results from dysregulated proteolytic activity, mainly by neutrophil elastase (HNE), in the lung parenchyma. This is the result of a substantial reduction of circulating alpha-1-antitrypsin (AAT) and the presence in the plasma of inactive polymers of AAT. Moreover, some AAT mutants have reduced intrinsic activity toward HNE, as demonstrated for the common Z mutant, as well as for other rarer variants. Here we report the identification and characterisation of the novel AAT reactive centre loop variant Gly349Arg (p.G373R) present in the ExAC database. This AAT variant is secreted at normal levels in cellular models of AATD but shows a severe reduction in anti-HNE activity. Biochemical and molecular dynamics studies suggest it exhibits unfavourable RCL presentation to cognate proteases and compromised insertion of the RCL into β-sheet A. Identification of a fully dysfunctional AAT mutant that does not show a secretory defect underlines the importance of accurate genotyping of patients with pulmonary AATD manifestations regardless of the presence of normal levels of AAT in the circulation. This subtype of disease is reminiscent of dysfunctional phenotypes in antithrombin and C1-inibitor deficiencies so, accordingly, we classify this variant as the first pure functionally-deficient (type II) AATD mutant. Background 2 Severe alpha-1-antitrypsin deficiency (AATD, MIM #613490) affects approximately 1 in 2000 of 3 the Northern European population. It is associated with pathogenic variants of the SERPINA1 gene 4 (MIM #107400) which encodes alpha-1-antitrypsin (AAT). AAT is the archetypal member of the 5 serpin superfamily of serine-protease inhibitors [1]; its primary physiological role is to protect the 6 lung parenchyma from attack by the serine proteases neutrophil elastase (HNE), cathepsin G [2] 7 and proteinase 3 [3]. Mutations that reduce AAT plasma levels alter the balance between inhibitory 8 and proteolytic activity leading to early onset emphysema and COPD [4]. A subset of SERPINA1 9 pathogenic alleles, well represented by the common severe deficiency Z allele (E342K, p.E366K) 10 can lead to accumulation of the protein as ordered polymers within the endoplasmic reticulum (ER) 11 of hepatocytes [5], predisposing ZZ homozygotes to liver disease [6]. AAT polymers have been 12 also found in the circulation of AATD patients with different genotypes [7,8]; they are known to 13 exert pro-inflammatory functions by stimulating neutrophils and monocytes [9] and their presence 14 is likely to over-estimate the amount of active AAT in the circulation.
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AAT levels in the cell media from HEK293T and Hepa 1-6 transfected cells were determined by 74 ELISA ( Fig 3A) showing that in both cell lines, AAT G349R appears to be secreted at similar levels 75 of the wild-type M AAT (85.6% ± 12.5 MEAN±SD for HEK293T cells, 87.3 ± 6.6 for Hepa 1-6 76 cells). 77 Analysis of the extracellular AAT by non-denaturing PAGE also shows that AAT G349R is 78 exclusively monomeric in the cell media ( Fig 3B) , while the Z AAT polymerogenic and deficient 79 variant is present in the media primarily as high molecular weight oligomers. 80 In addition, we investigated the intracellular distribution of AAT between the NP40-soluble and -81 insoluble fractions. As previously reported [33] , the tendency of an AAT variant to accumulate in 82 the NP-40 insoluble fraction is a symptom of severe polymerogenic tendency. In Fig 3C the only 83 AAT variant to precipitate within the insoluble fraction is Z AAT. 84 In conclusion, the G349R variant does not exhibit a "classical" deficiency phenotype.
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The G349R alpha-1-antitrypsin variant is non-functional 87 A survey of the literature identified a protein engineering study in which the P10 alanine residue of 88 α 1 -antichymotrypsin was arbitrarily mutated to arginine to evaluate its ability to become 89 incorporated into β-sheet A upon cleavage. It was found that due to compensatory molecular 90 rearrangements of the α 1 -antichymotrypsin molecule, there was an increase in substrate behaviour 91 rather than an elimination of inhibitory activity [36] . Correspondingly, we undertook experiments to 92 assess the functional capability of G349R AAT, with a view to ascertaining the clinical impact of 93 this variant. 94 One of the characteristics of the serpin-enzyme complex is that it is stable in the presence of SDS 95 [13, 27] . We incubated the media of HEK293T cells expressing M or G349R with an equimolar or 
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To further confirm this dysfunctional behaviour, we measured the activity against porcine 100 pancreatic elastase (PPE), a tool serine protease sometimes used as a surrogate for HNE. After 101 incubation with an increasing ratio of AAT variants in the media of HEK293T cells, compared to 102 the inhibitory activity of the wild-type M (dashed line), the new variant (dotted line) showed no 103 signs of inhibitory activity ( Fig 4B) .
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The variant was also expressed in bacteria and purified to homogeneity. It was found that this 105 material required an 8-fold greater concentration to fully inhibit HNE than M AAT, representing an 106 around 80% decrease in activity ( Fig 4C, left panel) , and was entirely inactive against the tool 107 protease chymotrypsin (CHT) ( Fig 4C, right panel) . The exclusive presence of the cleaved form of 108 G349R AAT when tested with HNE ( Fig 4A) shows that the loop is still recognised by the protease, 115 for human proteases that could potentially cut the sequence introduced by the G349R substitution 116 (EAARAMFL), we identified plasma kallikrein (KLK), which recognises the P1-P1' sequence R-X, 117 as a candidate. Using the recombinant protein, it was found that indeed this variant is susceptible to 118 cleavage by KLK when incubated at equimolar ratio ( Fig 4D) .
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In conclusion, AAT G349R is a novel dysfunctional variant lacking effective inhibitory activity. . This is sufficient to greatly reduce inhibitory efficiency, as measured by the non-136 productive turnover of inhibitor [36] . A comparison with the equivalent residues in cleaved AAT 137 (PDB ID: 1EZX) shows that in order to accommodate the G349R mutation, similar shifts would be 138 required in Phe384 and Ala336, and one residue, Phe51, provides a more marked occlusion in AAT 139 with respect to Ile51 in alpha-1-antichymotrypsin ( Fig 5A) .
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As well as interference with β-sheet incorporation during inhibition, a glycine-to-arginine mutation 141 would be expected to result in angular restriction of the local protein backbone in the RCL-exposed The reactive centre loop is an exposed loop that exhibits relatively few interactions with the serpin However, inhibitory serpins exist as two conformations and must present a sequence that is 171 recognised by the target protease, and these facts impose evolutionary constraints on some positions 172 in the loop [1, 28] . Thus, mutations at certain positions can impair the interaction with a target 173 protease, permit non-productive degradation by other proteases, or perturb the inhibitory 174 mechanism by interfering with the accommodation of the RCL by β-sheet A. 175 An increasing number of gene variants are being discovered by exome or genome-wide sequencing 176 of large cohorts and made available in annotated databases such as ExAC or LOVD [26, 27, 39] .
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In the present study, we have shown that one such variant, G349R, is secreted normally in the 178 native form by cells, but would provide no protection against proteolytic activity due to its near- 
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We now report AAT Iners as the first-described, pure type II AATD variant. We have shown that 226 this variant is secreted at wild-type levels and would therefore not be identified in a patient by 227 conventionally used diagnostic protocols. However, as it is non-functional, a carrier is likely to 228 present the same susceptibility to lung disease as individuals with a recognised deficiency mutant.
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AATD type II mutants are likely to contribute to the under-diagnosed burden of disease in the 230 general population. Reagents and antibodies. Product details are listed in S1 Table. 234 235 The nucleotide (GGG>AGG) encoding the G349R AAT variant (rs12077) was identified in the with an arginine. The force field amber99-sb was used, with the PME method for Coulomb interactions and a Lennard-Jones potential with a cut-off of 10 Å for the short-range interactions.
Identification of G349R in population databases
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The initial structure was completed by addition of hydrogens and solvated with TIP3P water in a 294 simulation box with a minimum distance of 10 Å between solute and box boundaries. Na + and Cl − 295 ions were added to reproduce a salt concentration of 150 mM and to neutralize the system. All 296 simulations were conducted at 310 K. The system was first subjected to energy minimization, then 297 equilibration at constant volume for 100 ps, and at constant pressure for 100 ps was performed 298 before the production run at constant temperature and pressure. The temperature was kept constant 
